Mistral Pharma
Pharmascience Inc. is a leading Canadian pharmaceutical company founded in 1983, specializing in the manufacturing of generic, branded, and over-the-counter medicines. With a strong commitment to quality, innovation, and community support, it serves both domestic and international markets with a global reach in over 50 countries. The company invests heavily in R&D, maintains high regulatory standards, and is dedicated to making healthcare accessible and affordable worldwide.
Industries
Nr. of Employees
small (1-50)
Mistral Pharma
Montreal-Royalmount, 6111 Royalmount Avenue, Montreal, Quebec, H4P 2T4, Canada
Products
Perindopril arginine + amlodipine oral tablets (multiple strengths)
Generic fixed-dose combination oral tablets indicated for treatment of mild to moderate essential hypertension; multiple strength presentations for initial and maintenance therapy.
Rivaroxaban oral film-coated tablets (multiple strengths)
Generic oral anticoagulant tablets indicated for prevention and treatment of venous thromboembolism, stroke prevention in atrial fibrillation and reduction of atherothrombotic events, available in several strengths.
Dapagliflozin oral tablets (5 mg, 10 mg)
Generic SGLT2 inhibitor tablets for glycemic control in type 2 diabetes and for associated heart failure and chronic kidney disease indications as approved in local labeling.
Extended-release colchicine 0.5 mg tablets for cardiovascular risk reduction
Extended-release oral colchicine formulation developed via repurposing for reduction of cardiovascular events in patients with coronary artery disease, supported by investigator-led clinical trial data.
Perindopril arginine + amlodipine oral tablets (multiple strengths)
Generic fixed-dose combination oral tablets indicated for treatment of mild to moderate essential hypertension; multiple strength presentations for initial and maintenance therapy.
Rivaroxaban oral film-coated tablets (multiple strengths)
Generic oral anticoagulant tablets indicated for prevention and treatment of venous thromboembolism, stroke prevention in atrial fibrillation and reduction of atherothrombotic events, available in several strengths.
Dapagliflozin oral tablets (5 mg, 10 mg)
Generic SGLT2 inhibitor tablets for glycemic control in type 2 diabetes and for associated heart failure and chronic kidney disease indications as approved in local labeling.
Extended-release colchicine 0.5 mg tablets for cardiovascular risk reduction
Extended-release oral colchicine formulation developed via repurposing for reduction of cardiovascular events in patients with coronary artery disease, supported by investigator-led clinical trial data.
Services
End-to-end sterile injectable services including formulation development, aseptic fill/finish, lyophilized vials, liquid vials, prefilled syringes, and packaging for global markets.
Development, tech transfer and manufacture of low-volume tablets and capsules, long-acting and cytotoxic/high-potency formulations.
GLP-capable method development and validation, quantitative LC-MS/MS assays for small and large molecules, PK/TK reporting, immunogenicity and biomarker analysis.
Targeted LC-MS/MS testing services for nitrosamine and other impurities in APIs and finished products with customized method development and regulatory guidance support.
Operational support for clinical trials including supply of investigational products and matching placebos for investigator-led and repurposing studies.
National and international commercialization, out-licensing, distribution partnerships and local market support for generic and specialty medicines.
End-to-end sterile injectable services including formulation development, aseptic fill/finish, lyophilized vials, liquid vials, prefilled syringes, and packaging for global markets.
Development, tech transfer and manufacture of low-volume tablets and capsules, long-acting and cytotoxic/high-potency formulations.
GLP-capable method development and validation, quantitative LC-MS/MS assays for small and large molecules, PK/TK reporting, immunogenicity and biomarker analysis.
Targeted LC-MS/MS testing services for nitrosamine and other impurities in APIs and finished products with customized method development and regulatory guidance support.
Operational support for clinical trials including supply of investigational products and matching placebos for investigator-led and repurposing studies.
National and international commercialization, out-licensing, distribution partnerships and local market support for generic and specialty medicines.
Expertise Areas
- Generic drug development and manufacturing
- Sterile injectable development and manufacturing
- High-potency oral dosage manufacturing
- Contract development and manufacturing (CDMO)
Key Technologies
- LC-MS/MS bioanalytical assays
- GLP/GCP/GMP-regulated laboratory processes
- AI-driven supply chain and resupply planning
- Aseptic fill/finish and lyophilization
News & Updates
Pharmascience Canada expands its portfolio with a new treatment for Parkinson’s disease.
Introduction of a new antihistamine treatment to support patients.
Launch of a new medication for breast cancer treatment.
Introduction of a new medication to the market.
Announcement of drug coverage plan listings.
Distribution agreement for TransCon™ PTH in Canada.
Pharmascience Canada expands its portfolio with a new treatment for Parkinson’s disease.
Introduction of a new antihistamine treatment to support patients.
Launch of a new medication for breast cancer treatment.
Introduction of a new medication to the market.
Announcement of drug coverage plan listings.
Distribution agreement for TransCon™ PTH in Canada.